title: The results of pacing trials for the prevention and termination of atrial tachyarrhythmias: is there any evidence of therapeutic breakthrough?
abstract: Atrial fibrillation (AF) is now recognized as the most prevalent sustained cardiac arrhythmia and it is associated with considerable mortality and morbidity. The demand for effective therapeutic strategies for AF has always been high and is anticipated to further increase. Anticoagulation and pharmacologic antiarrhythmic therapy or radiofrequency catheter ablation remain the mainstay of treatment for AF. Among the wide range of nonpharmacologic options which are presently being investigated, only ablation in or around the pulmonary veins and the surgical maze procedure have been shown to accomplish the aim of the curative treatment of the arrhythmia. Preventative atrial pacing and antitachycardia pacing may offer an attractive alternative option for the management of AF by either eliminating the triggers and/or by modifying the substrate of the arrhythmia. The results of several recent trials have shown a significant increase in the time to first AF recurrence, a decrease in atrial conduction time, and a trend towards reduction in AF burden, suggesting that atrial pacing may prevent AF due to improved synchronization of atrial depolarization. The recognition of potential triggers of AF, such as atrial premature complexes, short-long sequence, and bradycardia, has encouraged the development of novel atrial pacing algorithms designed to prevent the initiation of the arrhythmia on an individual basis. Observations of AF often starting with regular atrial activity consistent with atrial tachycardia have supported the hypothesis that early antitachycardia pacing may prevent progression to AF. The concept of "hybrid therapy" based on the combination of several different therapeutic strategies suggests that antitachycardia pacing therapy, integrated with an atrial defibrillator and preventative atrial pacing modes, may act synergistically to prevent AF. Dual chamber cardioverter-defibrillators with capacity to prevent and interrupt AF may offer more comprehensive and successful treatment for patients with advanced heart disease, frequent paroxysms of AF, and the risk of proarrhythmia.
authors.affiliation: Department of Cardiological Sciences, St. George's Hospital Medical School, Cranmer Terrace, London SW1 0RE, United Kingdom.
authors.forename: Irina
authors.initials: I
authors.lastname: Savelieva
authors.forename: A John
authors.initials: AJ
authors.lastname: Camm
mesh_terms: D000465:Algorithms; D001281:Atrial Fibrillation / Q000503:physiopathology / Q000517:prevention & control* / Q000628:therapy; D002304:Cardiac Pacing, Artificial / Q000379:methods; D002986:Clinical Trials as Topic; D017147:Defibrillators, Implantable; D022062:Electrophysiologic Techniques, Cardiac; D006801:Humans; D010138:Pacemaker, Artificial